<DOC>
	<DOC>NCT01190878</DOC>
	<brief_summary>The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy in topical administration of differing dosing regimens of ISV-303 compared to vehicle and Xibromâ„¢ when dosed for 2 weeks in post-cataract-surgery volunteers.</brief_summary>
	<brief_title>Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Bromfenac</mesh_term>
	<criteria>Scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation on the day prior to study enrollment Meet the best corrected visual acuity score requirement Meet the IOP requirement Additional inclusion criteria also apply Known hypersensitivity or poor tolerance to bromfenac sodium or any component of the study medications or any of the procedural medications Use of any ocular topical, or systemic medication that could interfere with normal lacrimation, wound healing, the test agent, or the interpretation of study results, within 1 week prior to Day of Surgery Additional exclusion criteria also apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>